Literature DB >> 31111764

Antidepressants, withdrawal, and addiction; where are we now?

Sameer Jauhar1, Joseph Hayes2, Guy M Goodwin3, David S Baldwin4, Philip J Cowen3, David J Nutt5.   

Abstract

Controversy continues with regard to antidepressants and withdrawal. Recent debates have focused on the prevalence and length of withdrawal, and some continue to state that withdrawal from these compounds constitutes 'addiction'. In this editorial we examine the evidence underlying these recent debates. We acknowledge gaps in knowledge, and make suggestions for how the field can progress.

Entities:  

Keywords:  Antidepressive agents; addiction; paroxetine; serotonin uptake inhibitors

Mesh：

Substances：

Year:  2019        PMID： 31111764      PMCID： PMC7613097          DOI： 10.1177/0269881119845799

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN： 0269-8811            Impact factor:   4.562


  29 in total

1.  Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study.

Authors:  David S Baldwin; Anna Karina Trap Huusom; Eli Maehlum
Journal:  Br J Psychiatry       Date:  2006-09       Impact factor: 9.319

2.  Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001-2004.

Authors:  Richard M Martin; Margaret May; David Gunnell
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

3.  A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.

Authors:  J S Price; P C Waller; S M Wood; A V MacKay
Journal:  Br J Clin Pharmacol       Date:  1996-12       Impact factor: 4.335

4.  Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.

Authors:  J F Rosenbaum; M Fava; S L Hoog; R C Ascroft; W B Krebs
Journal:  Biol Psychiatry       Date:  1998-07-15       Impact factor: 13.382

5.  Clinical experience with imipramine (G22355) in the treatment of depression.

Authors:  A M MANN; A S MACPHERSON
Journal:  Can Psychiatr Assoc J       Date:  1959-01

6.  A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?

Authors:  James Davies; John Read
Journal:  Addict Behav       Date:  2018-09-04       Impact factor: 3.913

7.  Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study.

Authors:  S Oehrberg; P E Christiansen; K Behnke; A L Borup; B Severin; J Soegaard; H Calberg; R Judge; J K Ohrstrom; P M Manniche
Journal:  Br J Psychiatry       Date:  1995-09       Impact factor: 9.319

8.  Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.

Authors:  Joanna Le Noury; John M Nardo; David Healy; Jon Jureidini; Melissa Raven; Catalin Tufanaru; Elia Abi-Jaoude
Journal:  BMJ       Date:  2015-09-16

9.  Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial.

Authors:  Nicola Wiles; Laura Thomas; Anna Abel; Nicola Ridgway; Nicholas Turner; John Campbell; Anne Garland; Sandra Hollinghurst; Bill Jerrom; David Kessler; Willem Kuyken; Jill Morrison; Katrina Turner; Chris Williams; Tim Peters; Glyn Lewis
Journal:  Lancet       Date:  2012-12-07       Impact factor: 79.321

10.  Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved.

Authors:  Thibault Renoir
Journal:  Front Pharmacol       Date:  2013-04-16       Impact factor: 5.810
View more
  4 in total

1.  The 'patient voice': patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition.

Authors:  Anne Guy; Marion Brown; Stevie Lewis; Mark Horowitz
Journal:  Ther Adv Psychopharmacol       Date:  2020-11-09

2.  A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases.

Authors:  Stefania Chiappini; Rachel Vickers-Smith; Amira Guirguis; John Martin Corkery; Giovanni Martinotti; Fabrizio Schifano
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-01

3.  Antidepressant withdrawal - the tide is finally turning.

Authors:  Michael P Hengartner; James Davies; John Read
Journal:  Epidemiol Psychiatr Sci       Date:  2019-08-22       Impact factor: 6.892

4.  Concern about addiction is associated with lower quality of life in patients with osteoarthritis: an exploratory, real-world data analysis.

Authors:  Louis P Garrison; Patricia Schepman; Andrew G Bushmakin; Rebecca L Robinson; Leslie Tive; Jerry Hall; Mendwas Dzingina; James Jackson; Mia Berry; Joseph C Cappelleri; Stuart Silverman
Journal:  Qual Life Res       Date:  2021-07-05       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.